Galapagos Acquires Inpharmatica In All-Share Transaction
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal gives Galapagos access to new clients, including Pfizer and Genentech.
You may also be interested in...
Galapagos Seeks Partner For Recently Acquired Low-Dose Estrogen Product
The firm continues its acquisition program with the purchase of ProStrakan’s bone disease unit for a maximum value of $60 million.
Galapagos Seeks Partner For Recently Acquired Low-Dose Estrogen Product
The firm continues its acquisition program with the purchase of ProStrakan’s bone disease unit for a maximum value of $60 million.
GSK’s External Alliances Evolve With Galapagos Partnership
Deal between GSK’s Center of Excellence for External Drug Discovery and Galapagos will focus on osteoarthritis treatments.